Page 87 - Read Online

Author Instructions

submitted to any OAE journals.
7. Policy of the Use of AI and AI-assisted Technologies in Scientific Writing
Authorship credit of RDODJ should be solely based on substantial contributions to a published study, as specified in the
Generative AI and AI-assisted technologies (e.g., large language models) are expected to be increasingly used to create
content. In the writing process of manuscripts, using AI and AI-assisted technologies to complete key researcher work,
such as producing scientific insights, analyzing and interpreting data or drawing scientific conclusions, is not allowed, and
they should only be used to improve the readability and language of manuscripts.
AI and AI-assisted technologies should be used under human control and supervision as they may generate incorrect or
prejudiced output, and they should not be listed as an author or co-author, nor cited as an author.
The use of AI and AI-assisted technologies should be disclosed by authors in their manuscripts, and a statement will be
required in the final publication.
OAE will keep monitoring the development and adjust the policy when necessary.

8. Conflict of Interests
RDODJ require authors to declare any possible financial and/or non-financial conflicts of interest at the end of their
manuscript and in the cover letter, as well as confirm this point when submitting their manuscript in the submission system.
If no conflicts of interest exist, authors need to state “The authors declare no conflicts of interest”. We also recognize that
some authors may be bound by confidentiality agreements, in which cases authors need to sate “The authors declare that
they are bound by confidentiality agreements that prevent them from disclosing their competing interests in this work”.

9. Editorial Process
9.1 Initial check
9.1.1 Initial manuscript check
New submissions are initially checked by the Managing Editor from the perspectives of originality, suitability, structure
and formatting, conflicts of interest, background of authors, etc. Poorly-prepared manuscripts may be rejected at this stage.
If your manuscript does not meet one or more of these requirements, we will return it for further revisions.

9.1.2 Publishing ethics
All manuscripts submitted to RDODJ are screened using iThenticate powered by CrossCheck to identify any plagiarized
content. Your study must also meet all ethical requirements as outlined in our Editorial Policies. If the manuscript does not
pass any of these checks, we may return it to you for further revisions or decline to consider your study for publication.
9.2 Editorial assessment
Once your manuscript has passed the initial manuscript check, it will be assigned to an Assistant Editor, and then the
Editor-in-Chief, or an Associate Editor in the case of a conflict of interest, will be notified of the submission and invited to
review. Regarding Special Issue paper, after passing the initial check, the manuscript will be successively assigned to an
Assistant Editor, Guest Editor, and then to the Editor-in-Chief, or an Associate Editor in the case of conflict of interest for
the Editor-in-Chief to review. The Editor-in-Chief, or the Associate Editor may reject manuscripts that they deem highly
unlikely to pass peer review without further consultation. Once your manuscript has passed the editorial assessment, the
Assistant Editor will start to organize peer-review.

9.3 Process
RDODJ operates a single-blind review process. The technical quality of the research described in the manuscript is assessed
by a minimum of three independent expert reviewers. The Editor-in-Chief is responsible for the final decision regarding
acceptance or rejection of the manuscript. For controversial manuscripts, the Editor-in-Chief is responsible for making the
final decision.
9.4 Decisions
Your research will be judged on technical soundness only, not on its perceived impact as judged by Editors or referees.
There are three possible decisions: Accept (your study satisfies all publication criteria), Invitation to Revise (more work is
required to satisfy all criteria), and Reject (your study fails to satisfy key criteria and it is highly unlikely that further work
can address its shortcomings).
10. Contact Us
Journal Contact
Rare Disease and Orphan Drugs Journal Editorial Office
Suite 1504, Plaza A, Xi’an National Digital Publishing Base, No. 996 Tiangu 7th Road, Gaoxin District, Xi’an 710077,
Shaanxi, China.
Tel: +86 (0)29 8954 0089
Yuan Ding
Managing Editor
editorialoffice@rdodjournal.com
Last updated on 17 July, 2023

XIV Rare Disease and Orphan Drugs Journal | Volume 2 | Issue 2 | Jun 2023 ¦